Department of Oncology
Andrew R. Belch has not added Biography.
If you are Andrew R. Belch and would like to personalize this page please email our Author Liaison for assistance.
Intraclonal homogeneity of clonotypic immunoglobulin M and diversity of nonclinical post-switch isotypes in multiple myeloma: insights into the evolution of the myeloma clone.
Clinical cancer research : an official journal of the American Association for Cancer Research Feb, 2002 | Pubmed ID: 11839670
Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice.
Experimental hematology Mar, 2002 | Pubmed ID: 11882359
CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications.
Journal of immunotherapy (Hagerstown, Md. : 1997) Jan-Feb, 2002 | Pubmed ID: 11924912
Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34 (+) hematopoietic progenitors.
Clinical cancer research : an official journal of the American Association for Cancer Research Oct, 2002 | Pubmed ID: 12374689
Differential expression of human equilibrative nucleoside transporter 1 (hENT1) protein in the Reed-Sternberg cells of Hodgkin's disease.
Leukemia & lymphoma Jul, 2002 | Pubmed ID: 12389626
In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression.
Blood Feb, 2003 | Pubmed ID: 12393535
The malignant clone in Waldenstrom's macroglobulinemia.
Seminars in oncology Apr, 2003 | Pubmed ID: 12720122
Abnormal expression of hyaluronan synthases in patients with Waldenstrom's macroglobulimenia.
Seminars in oncology Apr, 2003 | Pubmed ID: 12720129
Clonotypic IgM V/D/J sequence analysis in Waldenstrom macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral blood.
Blood Oct, 2004 | Pubmed ID: 14764523
RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma.
Blood Aug, 2004 | Pubmed ID: 15105292
Association between exercise and quality of life in multiple myeloma cancer survivors.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer Nov, 2004 | Pubmed ID: 15322968
Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant.
Clinical cancer research : an official journal of the American Association for Cancer Research Dec, 2004 | Pubmed ID: 15623591
Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients.
Blood May, 2005 | Pubmed ID: 15677557
Receptor for hyaluronan-mediated motility correlates with centrosome abnormalities in multiple myeloma and maintains mitotic integrity.
Cancer research Feb, 2005 | Pubmed ID: 15705883
Intronic splicing of hyaluronan synthase 1 (HAS1): a biologically relevant indicator of poor outcome in multiple myeloma.
Blood Jun, 2005 | Pubmed ID: 15731173
Origins of Waldenstrom's macroglobulinemia: does it arise from an unusual B-cell precursor?
Clinical lymphoma Mar, 2005 | Pubmed ID: 15794851
Potential impact of a single nucleotide polymorphism in the hyaluronan synthase 1 gene in Waldenstrom's macroglobulinemia.
Clinical lymphoma Mar, 2005 | Pubmed ID: 15794859
Sensitive detection using microfluidics technology of single cell PCR products from high and low abundance IgH VDJ templates in multiple myeloma.
Journal of immunological methods Oct, 2005 | Pubmed ID: 16150455
SSX cancer testis antigens are expressed in most multiple myeloma patients: co-expression of SSX1, 2, 4, and 5 correlates with adverse prognosis and high frequencies of SSX-positive PCs.
Journal of immunotherapy (Hagerstown, Md. : 1997) Nov-Dec, 2005 | Pubmed ID: 16224274
Impaired class switch recombination (CSR) in Waldenstrom macroglobulinemia (WM) despite apparently normal CSR machinery.
Blood Apr, 2006 | Pubmed ID: 16317092
Understanding the determinants of exercise intentions in multiple myeloma cancer survivors: an application of the theory of planned behavior.
Cancer nursing May-Jun, 2006 | Pubmed ID: 16783115
Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma.
Leukemia & lymphoma Nov, 2006 | Pubmed ID: 17107900
Molecular characterization of Waldenstrom's macroglobulinemia reveals frequent occurrence of two B-cell clones having distinct IgH VDJ sequences.
Clinical cancer research : an official journal of the American Association for Cancer Research Apr, 2007 | Pubmed ID: 17404080
Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index.
Blood Aug, 2007 | Pubmed ID: 17475910
Microfluidic chips for detecting the t(4;14) translocation and monitoring disease during treatment using reverse transcriptase-polymerase chain reaction analysis of IgH-MMSET hybrid transcripts.
The Journal of molecular diagnostics : JMD Jul, 2007 | Pubmed ID: 17591936
The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma.
British journal of haematology Feb, 2008 | Pubmed ID: 18076711
A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma.
Blood Oct, 2008 | Pubmed ID: 18535198
Analysis of clonotypic switch junctions reveals multiple myeloma originates from a single class switch event with ongoing mutation in the isotype-switched progeny.
Blood Sep, 2008 | Pubmed ID: 18577707
Treatment of relapsed and refractory myeloma.
Leukemia & lymphoma Aug, 2008 | Pubmed ID: 18608859
Inherited and acquired variations in the hyaluronan synthase 1 (HAS1) gene may contribute to disease progression in multiple myeloma and Waldenstrom macroglobulinemia.
Blood Dec, 2008 | Pubmed ID: 18815290
Altered expression of fibronectin and collagens I and IV in multiple myeloma and monoclonal gammopathy of undetermined significance.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society Mar, 2009 | Pubmed ID: 19001640
High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program.
British journal of haematology Jan, 2009 | Pubmed ID: 19036114
Genetic abnormalities in Waldenström's macroglobulinemia.
Clinical lymphoma & myeloma Mar, 2009 | Pubmed ID: 19362966
Promiscuity of translocation partners in multiple myeloma.
Journal of cellular biochemistry Apr, 2010 | Pubmed ID: 20127714
Multiple myeloma may include microvessel endothelial cells of malignant origin.
Leukemia & lymphoma Apr, 2010 | Pubmed ID: 20233053
In a patient with biclonal Waldenstrom macroglobulinemia only one clone expands in three-dimensional culture and includes putative cancer stem cells.
Leukemia & lymphoma Feb, 2011 | Pubmed ID: 21133724
Expression, adverse prognostic significance and therapeutic small molecule inhibition of Polo-like kinase 1 in multiple myeloma.
Leukemia research Dec, 2011 | Pubmed ID: 21816470
Multiple Myeloma Includes Phenotypically Defined Subsets of Clonotypic CD20+ B Cells that Persist During Treatment with Rituximab.
Clinical medicine. Oncology , 2008 | Pubmed ID: 21892289
Differential positioning and close spatial proximity of translocation-prone genes in nonmalignant B-cells from multiple myeloma patients.
Genes, chromosomes & cancer Aug, 2012 | Pubmed ID: 22489023
In multiple myeloma, bone-marrow lymphocytes harboring the same chromosomal abnormalities as autologous plasma cells predict poor survival.
American journal of hematology Jun, 2012 | Pubmed ID: 22495885
In non-transplant patients with multiple myeloma, the pre-treatment level of clonotypic cells predicts event-free survival.
Molecular cancer , 2012 | Pubmed ID: 23083101
Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Feb, 2013 | Pubmed ID: 23233702
Alteration of introns in a hyaluronan synthase 1 (HAS1) minigene convert Pre-mRNA [corrected] splicing to the aberrant pattern in multiple myeloma (MM): MM patients harbor similar changes.
PloS one , 2013 | Pubmed ID: 23301075
Differential nuclear organization of translocation-prone genes in nonmalignant B cells from patients with t(14;16) as compared with t(4;14) or t(11;14) myeloma.
Genes, chromosomes & cancer Jun, 2013 | Pubmed ID: 23460268
Aberrant splicing, hyaluronan synthases and intracellular hyaluronan as drivers of oncogenesis and potential drug targets.
Current cancer drug targets May, 2013 | Pubmed ID: 23517594
The systemic cytokine environment is permanently altered in multiple myeloma.
PloS one , 2013 | Pubmed ID: 23544044
Frequent occurrence of highly expanded but unrelated B-cell clones in patients with multiple myeloma.
PloS one , 2013 | Pubmed ID: 23724106
JoVE 소개
Copyright © 2024 MyJoVE Corporation. 판권 소유